NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, protein immune profiling, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, nCounter Vantage 3D, miRNA expression, cancer copy number variation, and other gene expression panels. Further, the company offers nCounter-based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc., as well as the Cancer Therapy Evaluation Program of the National Cancer Institute. The company was founded in 2003 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NSTG
CUSIPN/A
Phone206-378-6266
Debt
Debt-to-Equity Ratio1.97
Current Ratio3.29
Quick Ratio2.67
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$114.90 million
Price / Sales3.25
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book9.18
Profitability
EPS (Most Recent Fiscal Year)($1.84)
Net Income$-43,560,000.00
Net Margins-36.62%
Return on Equity-108.29%
Return on Assets-31.72%
Miscellaneous
Employees467
Outstanding Shares25,750,000
NanoString Technologies (NASDAQ:NSTG) Frequently Asked Questions
What is NanoString Technologies' stock symbol?
NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."
How were NanoString Technologies' earnings last quarter?
NanoString Technologies Inc (NASDAQ:NSTG) released its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.75) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.76) by $0.01. The biotechnology company earned $23.09 million during the quarter, compared to analyst estimates of $21.48 million. NanoString Technologies had a negative return on equity of 108.29% and a negative net margin of 36.62%. View NanoString Technologies' Earnings History.
When is NanoString Technologies' next earnings date?
What price target have analysts set for NSTG?
4 equities research analysts have issued 12-month price objectives for NanoString Technologies' stock. Their predictions range from $12.00 to $20.00. On average, they anticipate NanoString Technologies' stock price to reach $15.6667 in the next year. View Analyst Ratings for NanoString Technologies.
Who are some of NanoString Technologies' key competitors?
Some companies that are related to NanoString Technologies include Acorda Therapeutics (ACOR), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Iovance Biotherapeutics (IOVA), DBV Technologies (DBVT), BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX) and Scholar Rock (SRRK).
Who are NanoString Technologies' key executives?
NanoString Technologies' management team includes the folowing people:
- Mr. R. Bradley Gray, CEO, Pres & Director (Age 41)
- Mr. J. Chad Brown, Sr. VP of Sales & Marketing (Age 60)
- Dr. Joseph M. Beechem, Sr. VP of R&D (Age 60)
- Mr. K. Thomas Bailey, CFO & Treasurer (Age 49)
- Dr. Mary Tedd Allen, Sr. VP of Operations (Age 55)
Has NanoString Technologies been receiving favorable news coverage?
Press coverage about NSTG stock has trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NanoString Technologies earned a daily sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.77 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are NanoString Technologies' major shareholders?
NanoString Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.94%), Neuberger Berman Group LLC (3.99%), Millennium Management LLC (3.32%), Altrinsic Global Advisors LLC (2.04%), Northern Trust Corp (0.94%) and Algert Global LLC (0.80%). Company insiders that own NanoString Technologies stock include Barney Saunders, Charles P Waite Jr, David W Ghesquiere, James A Johnson, R Bradley Gray, Wayne Burns and William Young. View Institutional Ownership Trends for NanoString Technologies.
Which institutional investors are selling NanoString Technologies stock?
NSTG stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Millennium Management LLC, Spark Investment Management LLC, Wells Fargo & Company MN, Neuberger Berman Group LLC, Northern Trust Corp and Lakeview Capital Partners LLC. View Insider Buying and Selling for NanoString Technologies.
Which institutional investors are buying NanoString Technologies stock?
NSTG stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Algert Global LLC, Platinum Investment Management Ltd., Citadel Advisors LLC, Altrinsic Global Advisors LLC and Baird Financial Group Inc.. View Insider Buying and Selling for NanoString Technologies.
How do I buy shares of NanoString Technologies?
Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NanoString Technologies' stock price today?
One share of NSTG stock can currently be purchased for approximately $14.50.
How big of a company is NanoString Technologies?
NanoString Technologies has a market capitalization of $367.98 million and generates $114.90 million in revenue each year. The biotechnology company earns $-43,560,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. NanoString Technologies employs 467 workers across the globe.
How can I contact NanoString Technologies?
NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]
MarketBeat Community Rating for NanoString Technologies (NSTG)
MarketBeat's community ratings are surveys of what our community members think about NanoString Technologies and other stocks. Vote "Outperform" if you believe NSTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
